New antipsychotics for the treatment of schizophrenia
DOI:
https://doi.org/10.1590/S0101-60832007000800009Keywords:
Antipsychotics, neuroleptics, asenapine, ACP-103, bifeprunox, paliperidone, long acting injectable risperidone, sertindoleAbstract
BACKGROUND: The second generation antipsychotics represent the great achievement in the treatment of schizophrenia of the last decades. However in the last years some new antipsychotics were synthesized and such new compounds may represent great perspectives for the field of the treatment of schizophrenia. Some of these compounds are in use while others are still on evaluation through clinical trials. OBJECTIVE: Summarize the current knowledge of new antipsychotics. METHODS: PubMed search as well literature provided by the manufactures. RESULTS AND CONCLUSIONS: We present the main pharmacological characteristics as well as profiles of efficacy, security and tolerability of the following compounds: Asenapine, ACP-103, Bifeprunox, Paliperidone, Long Acting Injectable Risperidone and Sertindole.Downloads
Downloads
Published
2007-01-01
Issue
Section
Reviews of Literature
License
Once accepted for publication, the manuscript becomes permanent property of the Archives of Clinical Psychiatry. This copyright transfer subsumes exclusive and unlimited entitlement of the Archives of Clinical Psychiatry to publish and distribute the full contents of articles in whichever publishing medium, including press and electronic media, in Brazil and abroad.
Manuscripts are accepted with the understanding that the Editor and the editorial staff have the right to make revisions aimed at greater conciseness, clarity, and conformity with Journal style, of course without changing its content.
How to Cite
New antipsychotics for the treatment of schizophrenia . (2007). Archives of Clinical Psychiatry (São Paulo), 34(supl.2), 193-197. https://doi.org/10.1590/S0101-60832007000800009